Answers are grounded in this paper and cite their sources.
Classic Hodgkin lymphoma (cHL) shares overlapping histologic features with several morphologic mimics, most notably anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma (PTCL), and several large B-cell lymphomas.Immunohistochemistry is therefore indispensable for accurate diagnosis.Three markers form the practical core of this process.CD3 confirms or excludes T-cell lineage, CD15 supports the classic Hodgkin and Reed-Sternberg (HRS) cell phenotype, and CD30 is the most sensitive marker of both HRS cells and ALCL cells.Each marker has recognized limitations when used alone.CD15 has imperfect sensitivity and specificity, CD3 can be aberrantly expressed in B-cell neoplasms and lost in ALCL, and CD30 can show low or discordant expression.Interpreted together, the three markers generate a characteristic immunophenotypic signature.This signature helps distinguish cHL from nodular lymphocyte-predominant Hodgkin lymphoma, ALCL, PTCL, T-cell/histiocyte-rich large B-cell lymphoma, mediastinal gray zone lymphoma, and reactive processes.This narrative review summarizes the biology, diagnostic performance, and combined interpretation of CD3, CD15, and CD30 within the 2022 World Health Organization and International Consensus classifications.It presents a pattern-based comparison and a stepwise algorithm across major lymphoma subtypes.It also discusses diagnostic pitfalls, the limits of the available evidence, and the prognostic and therapeutic relevance of the panel, including CD30-directed brentuximab vedotin.
No takes yet. Share an insight, caveat, or question.
Elmahdi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: